Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction
2022/04/25 by Jawad H. Butt, Pooja Dewan, Béla Merkely +26 · 26 citations
Medicine · #Diabetes Treatment and Management #Heart Failure Treatment and Management #Cardiovascular Function and Risk Factors
paper · doi:10.7326/m21-4776
Abstract
BACKGROUND: Frailty may modify the risk-benefit profile of certain treatments, and frail patients may have reduced tolerance to treatments. OBJECTIVE: To investigate the efficacy of dapagliflozin according to frailty status, using the Rockwood cumulative deficit approach, in DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure). DESIGN: Post hoc analysis of a phase 3 randomized clinical trial. (ClinicalTrials.gov: NCT03036124). SETTING: 410 sites in 20 countries. PATIENTS: Patients with symptomatic heart failure (HF) with a left ventricular ejection fraction of 40% or less and elevated natriuretic peptide. INTERVENTION: Addition of once-daily 10 mg of dapagliflozin or placebo to guideline-recommended therapy. MEASUREMENTS: The primary outcome was worsening HF or cardiovascular death. RESULTS: Of the 4744 patients randomly assigned in DAPA-HF, a frailty index (FI) was calculable in 4742. In total, 2392 patients (50.4%) were in FI class 1 (FI ≤0.210; not frail), 1606 (33.9%) in FI class 2 (FI 0.211 to 0.310; more frail), and 744 (15.7%) in FI class 3 (FI ≥0.311; most frail). The median follow-up time was 18.2 months. Dapagliflozin reduced the risk for worsening HF or cardiovascular death, regardless of FI class. The differences in event rate per 100 person-years for dapagliflozin versus placebo from lowest to highest FI class were -3.5 (95% CI, -5.7 to -1.2), -3.6 (CI, -6.6 to -0.5), and -7.9 (CI, -13.9 to -1.9). Consistent benefits were observed for other clinical events and health status, but the absolute reductions were generally larger in the most frail patients. Study drug discontinuation and serious adverse events were not more frequent with dapagliflozin than placebo, regardless of FI class. LIMITATION: Enrollment criteria precluded the inclusion of very high-risk patients. CONCLUSION: Dapagliflozin improved all outcomes examined, regardless of frailty status. However, the absolute reductions were larger in more frail patients. PRIMARY FUNDING SOURCE: AstraZeneca.
Cited by
- The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus
- Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. [europepmc]
- Impact of frailty on disease-specific health status in cardiovascular disease. [europepmc]
- Phenotyping of Elderly Patients With Heart Failure Focused on Noncardiac Conditions: A Latent Class Analysis From a Multicenter Registry of Patients Hospitalized With Heart Failure. [europepmc]
- The association between chronic heart failure and frailty index: A study based on the National Health and Nutrition Examination Survey from 1999 to 2018. [europepmc]
- Frailty and Cardiovascular Mortality: A Narrative Review. [europepmc]
- The role of glucose in cardiac physiology and pathophysiology. [europepmc]
- Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart. [europepmc]
- Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty. [europepmc]
- Frailty and outcomes in heart failure patients from high-, middle-, and low-income countries. [europepmc]
- Frailty-Guided Management of Cardiovascular Disease-From Clinical Trials to Clinical Practice. [europepmc]
- mTORC1 and SGLT2 Inhibitors-A Therapeutic Perspective for Diabetic Cardiomyopathy. [europepmc]
- Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin. [europepmc]
- New statin use, mortality, and first cardiovascular events in older US Veterans by frailty status. [europepmc]
- Frailty in clinical drug trials: Frailty assessments, subgroup analyses and outcomes. [europepmc]
- Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia. [europepmc]
- Frailty and Cardiovascular Health. [europepmc]
- Unleashing frailty from laboratory into real world: A critical step toward frailty-guided clinical care of older adults. [europepmc]
- Frailty integration in medical specialties: Current evidence and suggested strategies from the Clin-STAR frailty interest group. [europepmc]
- The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required. [europepmc]
- Interacting and joint effects of frailty and inflammation on cardiovascular disease risk and the mediating role of inflammation in middle-aged and elderly populations. [europepmc]
- Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial. [europepmc]
- Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events. [europepmc]
- Advancing Cardiovascular, Kidney, and Metabolic Medicine: A Narrative Review of Insights and Innovations for the Future. [europepmc]
- Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. [europepmc]
- Metabolic Disturbances Involved in Cardiovascular Diseases: The Role of Mitochondrial Dysfunction, Altered Bioenergetics and Oxidative Stress. [europepmc]
Related